Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Samulski
Univ of North Carolina Chapel Hill, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Asklepios Biopharmaceutical (askbio), Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The SFIs of the investigator are related to the funded research since the technology being used in the project has been licensed to the company with which the investigator has multiple relationships.
The Institution has determined that since the technology could be further validated as a result of the research, these financial interests could conflict with project.
AAV Gene Therapy for AAT Deficiency
Adeno-associated virus (AAV) vectors are currently being employed in clinical trials of patients with alpha-one antitrypsin (AAT) deficiency. AAT deficiency clinical manifestations include both liver and lung disease resulting from nonfunctional protein accumulation in liver cells and a lack of circulating AAT, respectively. To prevent the liver disease, we have successfully used AAV vectors to deliver short hairpin RNA and suppress misfolded protein expression. Still, AAV gene therapy application in AAT deficiency faces several key restrictions pertaining to host immune response against the therapeutic vector - thus the proposed studies will carefully examine these immune responses and test several alternative solutions including development of novel AAV virions with improved liver-specific targeting and enhanced evasion from host immunity.
Filed on June 21, 2015.
Tell us what you know about Richard Samulski's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Richard Samulski filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | AskBio | $150,000 - $199,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical (askbio), Inc. | $150,000 - $199,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical (askbio), Inc. | $150,000 - $199,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | $20,000 - $39,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | $20,000 - $39,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | AskBio | $10,000 - $19,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical Inc. | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical Inc. | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical (askbio), Inc. | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | $0 - $4,999 |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios BioPharmaceutical, | $0 - $4,999 |
| Richard Jude Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios BioPharmaceutical | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios BioPharmaceutical, | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | AskBio | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical (askbio), Inc. | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical (askbio), Inc. | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Ask Bio, Inc | Value cannot be readily determined |
| Richard Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios Biopharmaceutical Inc. | Value cannot be readily determined |
| Richard Jude Samulski | Univ of North Carolina Chapel Hill | Conflict of Interest | Asklepios BioPharmaceutical | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.